• Lumos receives US$1.3 million purchase order for FebriDx from PHASE Scientific
• Order represents Lumos' largest for FebriDx to date
• Follows US FDA's 510(k) CLIA waiver clearance for FebriDx, unlocking US$1+ billion market opportunity

Lumos Diagnostics Holdings Ltd (ASX:LDX) has announced that it has received its largest purchase order to-date for its FebriDx product from PHASE Scientific ('PHASE'). The order, valued at US$1.3 million, comes shortly after the US FDA's 510(k) CLIA waiver clearance for FebriDx on 27 March 2026, which unlocks a US$1.0+ billion market opportunity and represents a 15x expansion of the addressable market for FebriDx. Lumos' CEO, Doug Ward, commented that receiving the largest order to-date so soon after the CLIA waiver is a strong validation of the commercial opportunity for FebriDx in the US market. Lumos looks forward to supporting PHASE as it scales its commercial rollout and drives adoption of FebriDx across the much broader pool of urgent and primary care settings.